Teprenone for preventing aggravation of COVID-19
Phase 2
- Conditions
- COVID-19
- Registration Number
- JPRN-jRCTs061200002
- Lead Sponsor
- ICHIHARA Eiki
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
1. 20 years-old or older
2. Confirmed diagnosis of COVID-19 with PCR or antigen test
3. temperature >= 37.5 degree Celsius
4. All subjects are required to have signed an informed consent document indicating that they understood the purpose of and procedures required for the study and are willing to participate in the study
Exclusion Criteria
1. Teprenon use within 2 weeks of study treatment
2. Patient who needs ventilator or ECMO
3. Active infectious disease requiring systemic treatment except for stable NTM
4. During pregnancy, within 28 days of postparturition, or during lactation.
5. Unidentified patient
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Intubation rate
- Secondary Outcome Measures
Name Time Method 1. Mortality<br>2. Period until fever relief<br>3. Oxygen dose<br>4. Change in chest CT images<br>5. Blood test values and theire rate of change<br>6. Severity<br>7. Period until discharge or lifting quarantine restrictions<br>8. Period until symptom disappearance<br>9. Adverse events